摘要 |
<p>The present invention relates to [1,2,4]triazolo[4,3-a quinoxaline derivatives of formula I <IMAGE> (I) wherein one of R1 and R2 is a 5- or 6-membered nitrogen-containing heterocyclic ring which is optionally substituted with one, two or three substituents, wherein each substituent is independently phenyl or C1-6-alkyl, or one of R1 and R2 is a fused ring system comprising a 5- or 6-membered nitrogen-containing heterocyclic ring and a benzene, pyridine, pyrimidine or pyrazine ring, wherein the fused ring system is optionally substituted with phenyl or C1-6-alkyl; and the other of R1 and R2 is hydrogen, C1-6-alkyl, C1-6-alkoxy, halogen, NO2, NH2, CN, CF3, COC1-6-alkyl or SO2NR'R'', wherein R' and R'' are independently hydrogen or C1-6-alkyl; and X is O or S; and pharmaceutically acceptable salts thereof. The compounds have affinity for the AMPA receptors and are antagonists in connection with this type of receptors which makes them useful in the treatment of CNS ailments, especially in the treatment of any of the numerous indications caused by hyperactivity of excitatory amino acids.</p> |